Study of a Cold Sore Patch for the Treatment of Herpes Labialis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide ( Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc. )
ClinicalTrials.gov Identifier:
NCT01484067
First received: November 30, 2011
Last updated: September 27, 2012
Last verified: September 2012
  Purpose

If a person qualifies to participate in this study, they will have an equal chance of being assigned to either of two groups. One group will receive a patch that they will need to carry with them, because as soon as a cold sore starts (within 1 hour) they will need to put the patch over the sore. The other group will not get a patch, but will need to follow the other instructions anyway.

When a subject's outbreak begins, they will need to return to the study center within 24 hours. Then they will return according to the appointments given within 10 days. If the study staff sees that their sore has healed enough before 10 days, subjects will be told that they don't need to return again.

As long as subjects are in the study, they will need to answer a few simple questions every day on a card or booklet called a diary, starting the first day of their outbreak. If a subject is assigned to the patch group, they must wear the patch all the time, taking it off only to replace it (if it gets loose, dirty, or unsightly) and at the study center, when they are asked to remove the patch so the sore can be checked.

During the study subjects will be allowed to use paracetamol for pain, but no other treatments or medicine. If they use paracetamol, subjects must record it in their diary. The study will be stopped, and there will be no subject visits or treatments during the end of year holiday break. If a subject experiences an outbreak during the holiday, they may follow their usual treatment routine.


Condition Intervention
Herpes Labialis
Device: Patch ( Compeed© Total CareTM Cold Sore Patch)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Clinician-Blind, Clinical Study to Examine the Safety and Performance of Compeed© Total Care™ Cold Sore Patch With Zinc Sulfate for the Treatment of Herpes Labialis

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Consumer and Personal Products Worldwide:

Primary Outcome Measures:
  • Overall Condition of Cold Sore [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Taking into account the size, physical impression of the lesion and overall quality of healing, clinician will score the overall condition of the cold sore on a scale of 0-10, where 0=Best and 10=Worst.

  • Erythema [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for erythema, where 0=none and 10=most severe

  • Edema [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for edema, where 0=none and 10=most severe

  • Vesicles [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for vesicles, where 0=none and 10=most severe

  • Scab/Crust [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Clinician's score on a scale of 0-10 for scab/crust, where 0=none and 10=most severe


Secondary Outcome Measures:
  • Lesion Size [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Measurement of lesion diameter

  • Lesion Stage [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]

    Lesion Stage on a categorical scale of 1-8, as described below:

    1. = prodrome (symptoms including itching, pain, tingling, but no physical evidence of disease by inspection or by palpation)
    2. = maculae (erythema)
    3. = papule (any elevation of skin without fluid; solid raised lesion)
    4. = vesicle (blister, fluid filled or collapsed)
    5. = ulcer/eroson (moist sore/wound)
    6. = soft crust/scab
    7. = hard crust/scab
    8. = healed (normal skin with no signs or symptoms; residual postlesion skin changes such as erythema, flaking, or slight asymmetry may be present)

  • Pain [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for unprovoked pain on a scale of 0-10, where 0=none and 10=most severe

  • Discomfort [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for discomfort on a scale of 0-10, where 0=none and 10=most severe

  • Itching [ Time Frame: Within 10 days ] [ Designated as safety issue: No ]
    Subject's score for itching on a scale of 0-10, where 0=none and 10=most severe

  • Burning [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for burning on a scale of 0-10, where 0=none and 10=most severe

  • Tingling [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for tingling on a scale of 0-10, where 0=none and 10=most severe

  • Swelling [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for swelling on a scale of 0-10, where 0=none and 10=most severe

  • Soreness/Tenderness [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for soreness/tenderness [upon touching] on a scale of 0-10, where 0=none and 10=most severe

  • Redness [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for redness on a scale of 0-10, where 0=none and 10=most severe

  • Blisters [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for blisters on a scale of 0-10, where 0=none and 10=most severe

  • Scab or Crust [ Time Frame: Within 10 Days ] [ Designated as safety issue: No ]
    Subject's score for scab or crust on a scale of 0-10, where 0=none and 10=most severe


Enrollment: 472
Study Start Date: November 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Patch
At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
Device: Patch ( Compeed© Total CareTM Cold Sore Patch)
A cold sore patch containing zinc sulfate
Other Name: Compeed© Total CareTM Cold Sore Patch
No Intervention: No Patch
No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.

Detailed Description:

This is a two-arm, randomized, clinician-blind study. No severe adverse effects are expected to be experienced in the control group. All subjects are allowed to treat cold sore related pain with an oral analgesic - paracetamol (APAP). The use of APAP for pain will be recorded as a concomitant medication. However, subjects will be required to refrain from using any additional treatment (topical or systemic) during study participation.

Subjects randomized to treatment will be instructed to initiate the therapy within 1 hour onset of their first sign or symptom and record their assessment in the diary card (for no treatment subjects, they will only record assessments upon onset of first sign or symptom). All subjects will return to the study center for clinical assessments within 24 hours and 48 hours after onset of first sign or symptom/initiation of treatment and every other day thereafter, with a final visit at Day 10 or at the time of completion/discontinuation if before Day 10. Diaries will be completed each day, beginning upon initiation of therapy (Day 0) and continuing until study completion/discontinuation, and will include information on study product applications.

Subjects assigned to a patch treatment will wear a patch continuously on their lesion and will apply a new patch on occasions where the patch becomes loose, falls off or becomes unsightly, including at study visits to the facility where subjects will be asked to remove their patch for clinical assessments. Treatment will continue until the lesion is healed, for a maximum of 10 days. As the test period will possibly extend through the end of year holiday break, subject visits and treatments will be halted during this break. All subjects who have not initiated therapy including subjects assigned no treatment group, will be allowed to use their regular therapy for a cold sore outbreak during the holiday break.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female or male 18-70 years old in good general health
  • Has a history of Herpes Labialis in the areas and with the frequency defined in the protocol.
  • Based on history, likely to experience a cold sore outbreak within next 2 to 3 months
  • Willing to provide informed consent
  • Willing to stop all other treatment of this condition and any topical products (lip balm, cosmetics, sunscreen) during test period
  • Women of child bearing potential must agree to use an adequate method of birth control (systemic birth control/intrauterine device)

Exclusion Criteria:

  • Self-reported to be pregnant, planning to become pregnant or nursing
  • Has any medical history or condition that might, per protocol or in the opinion of the investigator, compromise the subject's safety or the analysis of results.
  • Is taking or has taken within the 28 days before commencing treatment, protocol-specified medications or herbal supplements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01484067

Locations
United Kingdom
Intertek CRS
Manchester, United Kingdom, M15 6SE
Sponsors and Collaborators
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.
Investigators
Study Director: Clare Kendall Johnson & Johsnon Consumer and Personal Products Worldwide
  More Information

No publications provided

Responsible Party: Johnson & Johnson Consumer and Personal Products Worldwide ( Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc. )
ClinicalTrials.gov Identifier: NCT01484067     History of Changes
Other Study ID Numbers: HCOWDH0003, 44-DRM-HLS-11-002
Study First Received: November 30, 2011
Last Updated: September 27, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Johnson & Johnson Consumer and Personal Products Worldwide:
Herpes Simplex Virus

Additional relevant MeSH terms:
Herpes Labialis
Herpes Simplex
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Skin Diseases, Viral
Lip Diseases
Mouth Diseases
Stomatognathic Diseases
Skin Diseases, Infectious
Skin Diseases
Zinc Sulfate
Astringents
Physiological Effects of Drugs
Pharmacologic Actions
Dermatologic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 22, 2014